The management of postoperative COVID-19 pneumonia in a case with right pneumonectomy

Sağ pnömonektomi uygulanan bir olguda ameliyat sonrası COVID-19 pnömoni yönetimi

Bülent Mustafa Yenigün1, Farrukh Ibrahimov1, Yusuf Kahya1, Gökhan Kocaman1, Ezgi Gülten2, Mehrmet Serhat Birengel2, Cabir Yüksel2, Hakan Kütay2

1Department of Thoracic Surgery, Ankara University School of Medicine, Ankara, Turkey
2Department of Infectious Diseases and Clinical Microbiology, Ankara University School of Medicine, Ankara, Turkey

ABSTRACT

A 61-year-old male patient was hospitalized for the evaluation of a lung mass. The patient underwent right pneumonectomy. Although reverse-transcription polymerase chain reaction tests were negative for COVID-19, the diagnosis was supported by thoracic computed tomography. The patient responded to COVID-19 treatment, as evidenced by thoracic computed tomography. This case report highlights the importance of prompt diagnosis and treatment of COVID-19 in a patient who underwent pneumonectomy, which has high mortality and morbidity rates.

Keywords: Pneumonectomy, pneumonia, thoracic surgery.

ÖZ


Anahat sözüklər: Pnömonektomi; pnömoni, göğüs cerrahisi.

Coronavirus disease 2019 (COVID-19) is caused by a novel coronavirus, namely severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). The first case of COVID-19 was reported in Wuhan, China, in late December.[1] On March 2020, COVID-19 was declared as a pandemic by the World Health Organization (WHO). Patients with COVID-19 can be asymptomatic; however, the disease can progress to pneumonia, respiratory failure, and even death. Due to high mortality rates of COVID-19 and high occupancy rate in the intensive care units, many surgical associations have recommended ceasing all elective surgeries, until the transmission of COVID-19 has slowed. However, these recommendations are relatively complicated for thoracic surgeons, since most of their patients are oncological patients who should have surgery.[2]

In this article, we present a case of radiologically and clinically diagnosed with COVID-19 early after lung cancer surgery.

CASE REPORT

A 61-year-old male patient was hospitalized for the evaluation of a lung mass. Systemic examination was unremarkable and vital signs were stable. He had a 20 pack-year history of smoking. Evaluation of respiratory reserves have been as follows: forced expiratory volume (FEV1): 2.56 (67%), forced vital capacity (FVC): 2.64 (75%), and diffusing capacity...
for carbon monoxide (DLCO): 92%. Preoperative echocardiographic evaluation revealed no cardiac pathology and pulmonary artery pressure was 30 mmHg. A 70×45-mm sized mass located in the lower lobe of the right lung was observed on thoracic computed tomography (CT) (Figure 1). The major fissure was invaded by the mass. Positron emission tomography (PET) showed pathological 18F-fluorodeoxyglucose (FDG) uptake with a maximum standardized uptake value (SUV$_{\text{max}}$) of 17.8. The patient underwent bronchoscopy with endobronchial ultrasound (EBUS) for the evaluation of the mediastinal and hilar lymph nodes. Lymph node stations 2R,7 and 10R were sampled. The cytological diagnoses were found to be benign. An endobronchial lesion was observed inside the right lower lobe bronchus. A punch biopsy was taken from the lesion.

Histopathological examination was reported as a bronchial carcinoid tumor. The patient underwent right pneumonectomy and systematic mediastinal lymph node dissection through a right thoracotomy incision. The patient was discharged on postoperative Day 3 without any complication.

Table 1. Postoperative laboratory test results

<table>
<thead>
<tr>
<th>Postoperative</th>
<th>7th day</th>
<th>9th day</th>
<th>11th day</th>
<th>16th day</th>
<th>20th day</th>
<th>Reference range</th>
</tr>
</thead>
<tbody>
<tr>
<td>Leukocytes (×10⁹/L)</td>
<td>11.45</td>
<td>10.9</td>
<td>11.61</td>
<td>8.53</td>
<td>9.2</td>
<td>4.5-11</td>
</tr>
<tr>
<td>Lymphocytes (×10⁹/L)</td>
<td>1.9</td>
<td>1.45</td>
<td>1.54</td>
<td>2.55</td>
<td>1.98</td>
<td>1.5-4</td>
</tr>
<tr>
<td>Neutrophiles (×10⁹/L)</td>
<td>7.68</td>
<td>7.89</td>
<td>8.59</td>
<td>4.64</td>
<td>5.93</td>
<td>1.8-7.7</td>
</tr>
<tr>
<td>D-dimer (ng/mL)</td>
<td>732</td>
<td>3108</td>
<td>670</td>
<td>1073</td>
<td>117</td>
<td>0-243</td>
</tr>
<tr>
<td>C-reactive protein (mg/L)</td>
<td>55.6</td>
<td>97</td>
<td>83.4</td>
<td>31.3</td>
<td>21</td>
<td>0-5</td>
</tr>
</tbody>
</table>

On postoperative Day 9, the patient was admitted due to dry cough and dyspnea. Vital signs were as follows: blood pressure: 130/90 mmHg, respiration: 20 breaths/min, pulse: 90 bpm, body temperature: 37°C, and peripheral capillary oxygen saturation (SpO₂): 98% on ambient air. Breath sounds were not heard at the right hemithorax of the pneumonectomized patient. However, breath sounds were normal at the left hemithorax. Laboratory values were as follows: leukocyte:10.9×10⁹/L, lymphocytes:1.9×10⁹/L, D-dimer: 3108 ng/dL, and C-reactive protein (CRP): 97 mg/L (Table 1).

A nasopharyngeal swab sample was taken from the patient twice within 48 h. Also, pleural fluid samples were taken from the pneumonectomy cavity. Reverse-transcription polymerase chain reaction (RT-PCR) for SARS-CoV-2 was performed using all samples and all results were reported as negative. Thoracic CT revealed peripheral ground-glass opacity (GGO) with irregular contours located in left lung (Figures 2 and 3). The patient was isolated for 14 days. He was treated with oral hydroxychloroquine sulfate 200 mg b.i.d. for five days, oral azithromycin 500 mg daily for five days, oral oseltamivir 75 mg b.i.d. for five days, and intravenous piperacillin/tazobactam 4.5 g t.i.d. for seven days. Prophylactic dose of enoxaparin 4,000 IU once daily was added to the treatment to prevent the embolic complications of COVID-19. The patient was given O₂ (2L/min) through the nasal cannula during the hospital stay.

Histopathological examination was reported as an atypical bronchial carcinoid tumor and benign mediastinal lymph nodes. The Ki-67 proliferation index of the tumor was reported as 23%. Therefore, adjuvant chemotherapy was planned for the patient. Our patient was discharged after COVID-19 treatment and a 14-day isolation period. He is still under follow-up without any problems in our outpatient clinic.
DISCUSSION

The COVID-19 pandemic has forced hospitals to progressively reduce surgical volumes to both minimize disease transmission within the hospital and to preserve human and personal protective equipment and other resources needed to care for COVID-19 patients. However, it is very difficult to decide on the timing of oncological surgery during the pandemic. In this context, three options are available: (i) Surgery is not delayed; (ii) Surgery can be postponed; and (iii) The patient can be referred to an alternative therapy. These options should be discussed in the Multidisciplinary Tumor Councils. The first case of COVID-19 was confirmed in Turkey on March 11th, 2020. As our patient was hospitalized before this date, we did not postpone surgery.

Patients with COVID-19 have had a wide range of symptoms ranging from mild symptoms to severe illness. Common symptoms at the onset of illness are fever (98%), cough (76%), and myalgia or fatigue (44%), while dyspnea can be also seen in 55% of patients. Dyspnea and cough are expected symptoms in the early postoperative period in pneumonecтомized patients. The reasons can be listed as follows: decrease in respiratory capacity after resection, infection, bronchopleural fistula, and hemorrhage. However, as our hospital is a pandemic hospital, COVID-19 pneumonia was considered in the differential diagnosis of this patient.

A wide variety of thoracic CT findings in COVID-19 has been reported in the different studies. However, all studies indicate that the main thoracic CT feature of COVID-19 pneumonia is the presence of GGO (86%), typically with a peripheral and subpleural distribution. The other thoracic CT findings are consolidations (29%) and linear focal atelectatic changes (14%).[5] Peripherally located GGO and consolidation were also detected on thoracic CT in our patient. If COVID-19 pneumonia causes acute respiratory distress syndrome (30%), bilateral diffuse consolidations are observed in thoracic CT.[5-7]

The diagnosis of COVID-19 must be confirmed by SARS-CoV-2 RT-PCR testing. However, with limitations of sample collection and transportation and inadequate kit performance, the total positive rate of SARS-CoV-2 RT-PCR for throat swab samples was reported to be about 30 to 60% at the initial presentation. In the current emergency, the low sensitivity of SARS-CoV-2 RT-PCR implies that many COVID-19 patients can be unrecognized and cannot receive appropriate treatment in time. Such patients constitute a risk for infecting a larger population given the highly contagious nature of the virus. However, thoracic CT had a higher sensitivity for the diagnosis of COVID-19, compared to initial SARS-CoV-2 RT-PCR testing from swab samples.[6,7]

In a study by Ai et al.,[8] involving 1,014 patients in Wuhan, China who underwent both thoracic CT and SARS-CoV-2 RT-PCR testing, the authors reported 97% sensitivity of thoracic CT in suggesting COVID-19, based on positive SARS-CoV-2 RT-PCR results, and 75% in patients with negative SARS-CoV-2 RT-PCR results, but showing positive thoracic CT findings. They concluded that thoracic CT had a high sensitivity for the diagnosis of COVID-19 and could be considered as a primary tool for the current COVID-19 detection in epidemic areas. Another study by Li and Xia,[9] in 53 patients concluded that thoracic CT had a low rate of missed diagnosis of COVID-19 (3.9%, 2/51) and might be useful as a standard method for the rapid diagnosis of COVID-19.
to optimize the management of patients. In patients with negative SARS-CoV-2 RT-PCR results, if clinical and radiological findings are compatible with COVID-19, isolation and medical treatment should be started immediately.[8-10] Although SARS-CoV-2 RT-PCR results were negative in our patient, we immediately isolated our patient and started his treatment promptly.

In conclusion, no specific medication and vaccination is recommended to treat COVID-19 patients currently. However, governments and pharmaceutical companies are actively involved in the struggle of finding an effective drug to defeat the coronavirus as early as possible. Identifying infected individuals and advising them to self-isolate for the duration of the infection minimize the risk of transmission of the virus to the others, thereby, slowing the spread. In addition, patients undergoing pneumonectomy for lung cancer are thought to be at a high risk for the development of postoperative pulmonary complications and these complications are associated with high mortality rates. Pneumonia is considered as one of the most common and serious complications after pneumonectomy. If early and effective treatment is applied, pneumonia can be successfully treated in patients with pneumonectomy. Successful outcomes can be achieved with prompt diagnosis and treatment in patients with COVID-19 pneumonia after pneumonectomy.

Declaration of conflicting interests
The authors declared no conflicts of interest with respect to the authorship and/or publication of this article.

Funding
The authors received no financial support for the research and/or authorship of this article.

REFERENCES